1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 42 pages

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Immunomic Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc.
- The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Immunomic Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Immunomic Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Immunomic Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immunomic Therapeutics, Inc. Snapshot 5
Immunomic Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Immunomic Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immunomic Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Immunomic Therapeutics, Inc. - Pipeline Products Glance 14
Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Immunomic Therapeutics, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Immunomic Therapeutics, Inc. - Drug Profiles 18
TriMix-DC 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ASP-4070 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Cellular Immunotherapy for HIV 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
MC-LAMP-Vax 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
pp65 DC + Td 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ARA-LAMP-Vax 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
HIV-LAMP-Vax 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
TN-LAMP-vax 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Antigen mRNA Vaccine + LAMP 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
JCC-LAMP-Vax 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Multi-LAMP-Vax 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Immunomic Therapeutics, Inc. - Pipeline Analysis 34
Immunomic Therapeutics, Inc. - Pipeline Products by Target 34
Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration 35
Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type 36
Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action 37
Immunomic Therapeutics, Inc. - Recent Pipeline Updates 38
Immunomic Therapeutics, Inc. - Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables
Immunomic Therapeutics, Inc., Key Information 5
Immunomic Therapeutics, Inc., Key Facts 5
Immunomic Therapeutics, Inc. - Pipeline by Indication, 2016 8
Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9
Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10
Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016 12
Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Immunomic Therapeutics, Inc. - Phase II, 2016 14
Immunomic Therapeutics, Inc. - Phase I, 2016 15
Immunomic Therapeutics, Inc. - Preclinical, 2016 16
Immunomic Therapeutics, Inc. - Discovery, 2016 17
Immunomic Therapeutics, Inc. - Pipeline by Target, 2016 34
Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016 35
Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016 36
Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2016 38
Immunomic Therapeutics, Inc., Other Locations 40

List of Figures
Immunomic Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 7
Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9
Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10
Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 11
Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016 12
Immunomic Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 34
Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016 35
Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.